2023
Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whites
2022
Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group
Dicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group. Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.Peer-Reviewed Original ResearchConceptsIntra-operative frozen sectionOvarian germ cell tumorsGerm cell tumorsMalignant ovarian germ cell tumorsIntra-operative frozen section diagnosisFrozen section diagnosisCentral pathology reviewCell tumorsSurgical stagingAdolescent patientsFinal diagnosisFinal paraffin section diagnosisSection diagnosisFrozen sectionsParaffin section diagnosisOncology GroupPathology reviewCentral reviewOvarian germ cell malignanciesNonseminomatous germ cell tumorsGerm cell tumor componentsConfirmation of malignancyGerm cell malignanciesRecords of patientsChildren's Oncology Group
2021
Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol
Rodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB, Malkin D, Wasserman JD, de Oliveira Filho AG, LaQuaglia MP, Ward DA, Zambetti G, Mastellaro MJ, Pappo AS, Ribeiro RC. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal Of Clinical Oncology 2021, 39: 2463-2473. PMID: 33822640, PMCID: PMC8462560, DOI: 10.1200/jco.20.02871.Peer-Reviewed Original ResearchConceptsRetroperitoneal lymph node dissectionLymph node dissectionOutcomes of patientsAdrenocortical carcinomaNode dissectionStage IOncology GroupStage IV adrenocortical carcinomaStage-III adrenocortical carcinomaPediatric-specific studiesStage II diseaseEvent-free survivalStage II patientsThird of patientsOverall survival estimatesChildren's Oncology GroupHigh-risk groupCombination of mitotaneAggressive pediatric malignancyPediatric adrenocortical carcinomaAdvanced diseaseII patientsMultivariable analysisPoor outcomeExcellent outcomes
2020
Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trial
2019
α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensification
2018
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Fonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2018, 37: 396-402. PMID: 30576269, PMCID: PMC6553816, DOI: 10.1200/jco.18.00790.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsTumor marker elevationNongerminomatous malignant germ cell tumorsAbnormal tumor markersGerm cell tumorsMarker elevationTumor markersRelapse surveillanceOncology GroupInitial diagnosisCell tumorsChildren's Oncology GroupDetection of relapseSingle-arm trialNormal tumor markersCase report formsAbnormal imagingCentral reviewMarker levelsPathology reportsRelapsePatientsPhase IIIReport formsComplete dataComparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium
Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupEvent-free survivalOncology GroupClinical trialsGerm cell tumor patientsCarboplatin-based regimensCisplatin-based regimensParametric cure modelsLeukemia groupTumor patientsStandard riskChildren's CancerRegimensCancerRiskTrialsGroupCure modelPatientsCarboplatinInternational ConsortiumCisplatinTreatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study
Pashankar F, Frazier AL, Krailo M, Xia C, Pappo AS, Malogolowkin M, Olson TA, Rodriguez‐Galindo C. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatric Blood & Cancer 2018, 65: e27111. PMID: 29697191, PMCID: PMC6019185, DOI: 10.1002/pbc.27111.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsPediatric malignant germ cell tumorsGerm cell tumorsOncology GroupCell tumorsMarker declineRefractory germ cell tumorsHigh-dose chemotherapyPhase II trialChildren's Oncology GroupGroup of patientsLong-term toxicityRECIST responseSalvage therapyStable diseaseTIP regimenII trialRECIST criteriaElevated markersPartial responseProgressive diseaseStandard therapyAdditional administrationTumor markersPatients
2017
Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Villaluna D, Krailo M, Billmire DF, Rescorla FJ, Egler RA, Dicken BJ, Ross JH, Schlatter M, Rodriguez-Galindo C, Frazier AL. Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2017, 35: jco.2016.67.654. PMID: 28240974, PMCID: PMC5455599, DOI: 10.1200/jco.2016.67.6544.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsEvent-free survivalCycles of PEBEFS ratesGerm cell tumorsOncology GroupCell tumorsExtracranial malignant germ cell tumorsReduction of therapyChildren's Oncology GroupSingle-arm trialLow-stage tumorsHigh-stage tumorsAdministration of cisplatinEligible patientsComparable patientsHistorical cohortPatientsTumorsStatistical significanceComparable childrenPhase 3ChildrenP-valueOne-sided p-value
2016
Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children’s Oncology Group.
Shaikh F, Cullen J, Olson T, Pashankar F, Malogolowkin M, Amatruda J, Villaluna D, Krailo M, Billmire D, Rescorla F, Egler R, Dicken B, Ross J, Schlatter M, Rodriguez-Galindo C, Frazier A. Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children’s Oncology Group. Journal Of Clinical Oncology 2016, 34: 10512-10512. DOI: 10.1200/jco.2016.34.15_suppl.10512.Peer-Reviewed Original Research
2014
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States
Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, Shaikh F, Pashankar F, Stoneham S, Krailo M, Nicholson JC. Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal Of Clinical Oncology 2014, 33: 195-201. PMID: 25452439, PMCID: PMC4279239, DOI: 10.1200/jco.2014.58.3369.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAlpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolClinical Trials as TopicDisease-Free SurvivalEndodermal Sinus TumorEvidence-Based MedicineFemaleHumansMaleModels, StatisticalNeoplasm StagingNeoplasms, Germ Cell and EmbryonalPredictive Value of TestsPrognosisRetrospective StudiesRisk AssessmentRisk FactorsUnited KingdomUnited StatesConceptsGerm cell tumorsYolk sac tumorPediatric germ cell tumorsClinical trial dataAlpha-fetoproteinTumor siteOncology GroupCell tumorsMalignant pediatric germ cell tumorsPediatric extracranial germ cell tumorLong-term disease-free survivalEvidence-based risk stratificationExtracranial germ cell tumorsTrial dataPure yolk sac tumorPoor-risk groupStage IV diseaseDisease-free survivalPercentage of patientsChildren's Oncology GroupElevated alpha-fetoproteinPlatinum-based therapyClinical trial organizationsParametric cure modelsLeukemia groupSurveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group
Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL. Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group. Journal Of Clinical Oncology 2014, 32: 465-470. PMID: 24395845, PMCID: PMC4876316, DOI: 10.1200/jco.2013.51.1006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlpha-FetoproteinsAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinDisease-Free SurvivalEtoposideFemaleHumansInfantInfant, NewbornKaplan-Meier EstimateNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRadiographyRisk FactorsSalvage TherapyTime FactorsTreatment OutcomeConceptsMalignant ovarian germ cell tumorsStage I malignant ovarian germ cell tumorsOvarian germ cell tumorsEvent-free survivalGerm cell tumorsOverall survivalAlpha-fetoproteinRecurrent diseaseOncology GroupCell tumorsSuccessful Salvage ChemotherapyTumor marker elevationPercent of patientsKaplan-Meier methodChildren's Oncology GroupSerum tumor markersPredominant histologySalvage chemotherapyInitial surgeryMarker elevationMetastatic diseaseSurgical resectionMedian timeYolk sacTumor markers